Anthony C Keech
Overview
Explore the profile of Anthony C Keech including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
5896
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ong K, Januszewski A, Francis H, OConnell R, Mangani A, Li L, et al.
Diabetes Res Clin Pract
. 2025 Mar;
222:112080.
PMID: 40081501
Aims: Haptoglobin (HP) phenotype has been reported to modulate fenofibrate benefit on coronary artery disease in type 2 diabetes. It is unknown whether HP phenotype and levels modulate fenofibrate benefit...
2.
Halliday J, Russell-Green S, Lam B, Trawley S, McAuley S, Bach L, et al.
BMJ Open Diabetes Res Care
. 2025 Jan;
12(6.
PMID: 39797667
Introduction: This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy. Research Design And Methods: In this multicenter,...
3.
Robledo K, Marschner I, Grossmann M, Handelsman D, Yeap B, Allan C, et al.
Eur J Endocrinol
. 2024 Dec;
192(1):15-24.
PMID: 39720906
Objective: We have shown that men aged 50 years+ at high risk of type 2 diabetes treated with testosterone together with a lifestyle program reduced the risk of type 2...
4.
Jenkins A, Januszewski A, Kirby A, Hendrieckx C, McAuley S, Lee M, et al.
Intern Med J
. 2024 Nov;
55(1):148-153.
PMID: 39601386
Less than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID)...
5.
Januszewski A, Young H, Ong K, Li L, OConnell R, Lyons T, et al.
J Diabetes Investig
. 2024 Aug;
15(11):1663-1668.
PMID: 39171747
Aims/hypothesis: In diabetes haptoglobin (Hp) 2 vs Hp 1 allelic product is associated with cardiac and renal complications. Few studies report both Hp phenotype and Hp levels. In a Fenofibrate...
6.
Jenkins A, OConnell R, Januszewski A, Webster A, Davis T, Jardine M, et al.
Diabetes Res Clin Pract
. 2024 Mar;
210:111612.
PMID: 38479447
Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of...
7.
Tucker W, Tucker B, Januszewski A, Jenkins A, Keech A, Kestenbaum B, et al.
Clin Chim Acta
. 2024 Feb;
555:117799.
PMID: 38309558
Background: Fibroblast growth factor 21 (FGF21) levels are often elevated in cardiovascular disease (CVD). However, no study has assessed its association with cardiovascular and all-cause mortality in a population free...
8.
Rao B, Januszewski A, Brazionis L, OConnell R, Aryal N, Shimmin G, et al.
Intern Med J
. 2023 Nov;
53(11):2128-2131.
PMID: 37997276
In 6002 Australian adults with type 2 diabetes and a median 5-year follow-up in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, baseline socioeconomic status (SES) and self-reported...
9.
Figtree G, Vernon S, Harmer J, Gray M, Arnott C, Bachour E, et al.
J Am Coll Cardiol
. 2023 Sep;
82(13):1343-1359.
PMID: 37730292
Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals...
10.
Sheu A, OConnell R, Jenkins A, Tran T, Drury P, Sullivan D, et al.
Diabetes Metab Res Rev
. 2023 Mar;
39(5):e3631.
PMID: 36893361
Aims: Fracture risk is elevated in some type 2 diabetes patients. Bone fragility may be associated with more clinically severe type 2 diabetes, although prospective studies are lacking. It is...